Elanco FY21 rev $4,765M, adj EPS $1.05; Q4 adj EPS $0.21 (+75%); FY22 adj EPS guidance $1.18-1.24

Elanco Animal Health Inc

2021-FY EPS reported -$0.97 revenue$4,765,000,000

Full year 2021 revenue $4,765M (+46% YoY); reported EPS -$0.97, adjusted EPS $1.05.
Q4 2021 revenue $1,113M (-2% YoY); adjusted EPS $0.21 (+75% YoY).
FY22 guidance: revenue $4,745-$4,800M, adjusted EPS $1.18-$1.24.
Restructuring: ~380 positions cut; synergy target raised to $345M by 2023.
Board eliminated supermajority voting and adopted proxy access for 3%+ shareholders owning ≥3 years.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.